Extended indication Cabazitaxel Accord in combination with prednisone or prednisolone is indicated for the treatment of
Therapeutic value Possible equal value
Registration phase Registered

Product

Active substance Cabazitaxel
Domain Oncology and Hematology
Reason of inclusion Generic
Main indication Prostate cancer
Extended indication Cabazitaxel Accord in combination with prednisone or prednisolone is indicated for the treatment of adult patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen.
Current proprietary name Jevtana (Sanofi-Aventis)
Proprietary name Cabazitaxel Accord
Manufacturer Accord Healthcare
Mechanism of action Cytostatic

Registration

Registration route Centralised (EMA)
Submission date June 2019
Expected Registration August 2020
Registration phase Registered
Additional comments SPC Jevtana verloopt op 21 maart 2026. Positieve CHMP-opinie in april 2020.

Therapeutic value

Therapeutic value Possible equal value

Expected patient volume per year

Patiëntvolume is niet van toepassing bij generieke geneesmiddelen of biosimilars.

Expected cost per patient per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

Potential total cost per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.